Exenatide: A new option for the treatment of type 2 diabetes

Annals of Pharmacotherapy

Volumn 40, Issue 10, 2006, Pages 1777-1784

  Yoo, Bong Kyu ^a   Triller, Darren Michael ^b   Yoo, Dong Joo ^c  

^a Yeungnam University   (South Korea)

^b IPRO Inc   (United States)

^c Boston University   (United States)

Author keywords

Diabetes mellitus; Exenatide

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; CHLORPROPAMIDE; DIGOXIN; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; MEGLITINIDE; METFORMIN; MEVINOLIN; PHENYLALANINE DERIVATIVE; PLACEBO; SULFONYLUREA DERIVATIVE; TOLAZAMIDE;

ARTICLE; CLINICAL TRIAL; DATA EXTRACTION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EVALUATION; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; MEDLINE; NAUSEA; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMACH EMPTYING; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS, TYPE 2; HUMANS; PEPTIDES; VENOMS;

EID: 33749589088     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H060     Document Type: Article

References (35)

1. Raufman JP. Bioactive peptides from lizard venoms. Regul Pept 1996; 61:1-18.
2. Thorens B, Porret A, Buhler L, Deng S, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Diabetes 1993;42:1678-82.
3. Fehmann JC, Bode HP, Ebert T, Karl A, Goke B. Interaction of GLP-1 and leptin at rat pancreatic β-cells: effects on insulin secretion and signal transduction. Horm Metab Res 1997;29:572-6.
4. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagons-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126-31.
5. Kiefer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagons-like peptide 1 in vitro and in vivo by depeptidyl peptidase IV. Endocrinology 1995;136: 3585-96.
6. Joy SV, Rodgers PT, Scales AC. Incretin mimetics as emerging treatments for type 2 diabetes. Aim Pharmacother 2005;39:110-8. Epub 23 Nov 2004. DOI 10.1345/aph.1E245
7. Nishizawa M, Nakabayashi H, Kawai K, et al. The hepatic vagal reception of intraportal GLP-1 is via receptors different from the pancreatic GLP-1 receptor. J Auton Nerv Syst 2000;80:14-21.
8. Henquin J-C. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000;49:1751-60.
9. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001;50:583-9.
10. Kolterman O, Kim D, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62:173-81.
11. Abraham E, Leech C, Lin J, Zulewski H, Habener J. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 2002;143:3152-61.
12. Tourrel C, Bailbe D, Lacorne M, Meile M, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagons-like peptide-1 or exendin-4. Diabetes 2002;51:1443-52.
13. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88.
14. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptors signaling modulates β cell apoptosis. J Biol Chem 2003;278:471-8.
15. Harju E, Nordback I. Postprandial hyperglycemia after different carbohydrates in patients with total gastrectomy. Surg Gynecol Obstet 1987; 165:41-5.
16. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (AC2993) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-9.
17. Calara F, Taylor K, Han J, et al. A randomized, open-label, crossover study examining the effect of injection site of bioavailability of exenatide (synthetic exendin-4). Clin Ther 2005;27:210-5.
18. Prescribing information. Byetta (exenatide injection). Amylin Pharmaceuticals. www.byetta.com (accessed 2005 Nov 18).
19. Parkes DG, Young AA, Petrella E. Pharmacokinetics of exendin-4 in the rat following intravenous, subcutaneous and intraperitoneal administration (abstract). In: Proceedings of 81st Annual Meeting Endocrine Society 1999:216-7.
20. Linnebjerg H, Kothare P, Park S. Exenatide pharmacokinetics in patients with mild to moderate renal dysfunction and end stage renal disease (abstract 469-P). Presented at: 65th Scientific Sessions of the American Diabetes Association, San Diego, CA, June 10-14, 2005.
21. Kothare PA, Soon DK, Linnebjerg H, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol 2005;45: 1032-7.
22. Soon D, Linnebjerg H, Chan C, et al. Effect of exenatide on digoxin pharmacokinetics (abstract PO-047). In: Abstracts of the 8th World Congress on Clinical Pharmacology and Therapeutics 2004(suppl 1):A65.
23. Kothare P, Linnebjerg H, Atkins M, Mace K, Mitchell M. Effect of exenatide on lisinopril pharmacodynamics in patients treated for hypertension (abstract). In: Abstracts of the American Society for Clinical Pharmacology and Therapeutics Annual Meeting 2005:P14.
24. Blase E, Taylor K, Gao H, Wintle M, Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol 2005;45:570-7.
25. Buse J, Henry R, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35.
26. DeFronzo R, Ratner R, Han J, Kim D, Fineman M, Baron A. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28: 1092-100.
27. Kendall D, Riddle M, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91.
28. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69.
29. Fehse F, Trautmann M, Holst J, et al. Exenatide augments first and second phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005;90:5991-7.
30. Poon T, Nelson P, Shen L, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005;7:467-77.
31. Fineman M, Bicsak T, Shen L, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26:2370-7.
32. Fineman M, Shen L, Taylor K, Kim D, Baron D. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004;20:411-7.
33. Dupre J, Behme M, McDonald T. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 2004; 89:3469-73.
34. Egan J, Meneilly G, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 2003;284:E1072-9.
35. Drug topics red book update. Montvale, NJ: Thompson PDR, 2006.